<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="328">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01926171</url>
  </required_header>
  <id_info>
    <org_study_id>BD-IV-49</org_study_id>
    <nct_id>NCT01926171</nct_id>
  </id_info>
  <brief_title>Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases</brief_title>
  <official_title>A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Beta Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Beta Pharma Inc.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of icotinib in combination
      with whole brain radiotherapy for NSCLC patients with brain metastases. The primary endpoint
      is objective response rate of intracranial lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective response rate of intracranial lesions</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate of extracranial lesions</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with an objective response of extracranial lesions. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of intracranial lesions</measure>
    <time_frame>3-6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>All cause progress or mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6-12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All cause adverse events (AEs) and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib+WBRT</intervention_name>
    <description>Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.</description>
    <arm_group_label>Icotinib+WBRT</arm_group_label>
    <other_name>Commana</other_name>
    <other_name>BPI-2009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmation of non-small-cell lung cancer (NSCLC).

          -  Diagnosis of non-systematic brain metastases on a Gadolinium-enhanced MRI. More than
             2 sites of intracranial metastases, or the longest diameter of the intracranial
             lesion is more than 3cm.

          -  No other metastases except for brain metastases.

        Exclusion Criteria:

          -  Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
             erbitux.

          -  CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baotou Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Zhu, MD</last_name>
    <phone>86-18686111667</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wei Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
